MOZ-TIF2-mediated destruction of CBP/p300 is blocked by calpain inhibitor 2

Leukemia

Volumn 24, Issue 7, 2010, Pages 1359-1361

  Kindle, K B ^a   Collins, H M ^a   Heery, D M ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA ACTIN; CALPASTATIN; DOXYCYCLINE; HYBRID PROTEIN; LACTACYSTIN; NUCLEAR RECEPTOR COACTIVATOR 2; PROTEIN CBP; PROTEIN MOZ; PROTEIN P300; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; CYSTEINE PROTEINASE INHIBITOR; HISTONE ACETYLTRANSFERASE PCAF; MOZ-TIF2 PROTEIN, HUMAN; N-ACETYLLEUCYL-LEUCYL-METHIONINAL; OLIGOPEPTIDE; ONCOPROTEIN; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR BETA;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER CELL CULTURE; CELL STRAIN HEK293; DOWN REGULATION; DRUG INHIBITION; GENE REPRESSION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; LETTER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; BONE NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OSTEOSARCOMA; PATHOLOGY; PROMOTER REGION; TUMOR CELL CULTURE; WESTERN BLOTTING;

BLOTTING, WESTERN; BONE NEOPLASMS; CYSTEINE PROTEINASE INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGOPEPTIDES; ONCOGENE PROTEINS, FUSION; OSTEOSARCOMA; P300-CBP TRANSCRIPTION FACTORS; PROMOTER REGIONS, GENETIC; RECEPTORS, RETINOIC ACID; TUMOR CELLS, CULTURED;

EID: 77954656772     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.92     Document Type: Letter

References (8)

1. Troke PJ, Kindle KB, Collins HMA, Heery DM. MOZ fusion proteins in acute myeloid leukaemia. Biochem Soc Symp 2006;73:23-39.
2. Deguchi K, Ayton PM, Carapeti M, Kutok JL, Snyder CS, Williams IR et al. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell 2003;3:259-271.
3. Kindle KB, Troke PJ, Collins HM, Matsuda S, Bossi D, Bellodi C et al. MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function. Mol Cell Biol 2005;25:988-1002.
4. Huntly BJ, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004;6:587-596.
5. Collins HM, Kindle KB, Matsuda S, Ryan CM, Troke PJ, Kalkhoven E et al. MOZ-TIF2 alters cofactor recruitment and histone modification at the RARβ2 promoter: differential effects of MOZ fusion proteins on CBP-and MOZ-dependent activators. J Biol Chem 2006;281:17124-17133.
6. Matsuda S, Harries JC, Viskaduraki M, Troke PJ, Kindle KB, Ryan CM et al. A conserved α-helical motif mediates the binding of diverse nuclear proteins to the SRC1 interaction domain of CBP. J Biol Chem 2004;279:14055- 14064.
7. Waters L, Yue B, Veverka V, Renshaw P, Bramham J, Matsuda S et al. Structural diversity in p160/CREB-binding protein coactivator complexes. J Biol Chem 2006;281:14787-14795.
8. Rouaux C, Jokic N, Mbebi C, Boutillier S, Loeffler JP, Boutillier AL. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J 2003;22:6537-6549